91.20Open91.20Pre Close0 Volume4 Open Interest175.00Strike Price0.00Turnover60.33%IV5.21%PremiumDec 20, 2024Expiry Date78.01Intrinsic Value100Multiplier18DDays to Expiry13.19Extrinsic Value100Contract SizeAmericanOptions Type0.9979Delta0.0002Gamma3.23Leverage Ratio-0.0265Theta0.0844Rho3.22Eff Leverage0.0038Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet